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Abstract
Background: Community pharmacists are accessible health care professionals who encounter people with
lived experience of mental illness and addictions in daily practice. Although some existing research supports that
community pharmacists’ interventions result in improved patient mental health outcomes, gaps in knowledge
regarding the pharmacists’ experiences with service provision to this population remain. Improving knowledge
regarding the pharmacists’ experiences with mental illness and addictions service provision can facilitate a better
understanding of their perspectives and be used to inform the development and implementation of interventions
delivered by community pharmacists for people with lived experience of mental illness and addictions in communities.
Methods: We conducted a qualitative study using a directed content analysis and the Theoretical Domains Framework
as part of our underlying theory of behaviour change and our analytic framework for theme development.
The Theoretical Domains Framework facilitates understanding of behaviours of health care professionals and
implementation challenges and opportunities for interventions in health care. Thematic analysis co-occurred throughout
the process of the directed content analysis. We recruited community pharmacists, with experience dispensing
psychotropics, at a minimum, through multiple mechanisms (e.g., professional associations) in a convenience sampling
approach. Potential participants were offered the option of focus groups or interviews.
Results: Data were collected from one focus group and two interviews involving six pharmacists. Theoretical Domains
Framework coding was primarily weighted in two domains: social/professional role and identity and environmental
context and resources. We identified five main themes in the experiences of pharmacists in mental illness and addictions
care: competing interests, demands, and time; relationships, rapport, and trust; stigma; collaboration and triage; and role
expectations and clarity.
Conclusions: Pharmacists are not practicing to their full scope of practice in mental illness and addictions care for
several reasons including limitations within the work environment and lack of structures and processes in place to be
fully engaged as health care professionals. More research and policy work are needed to examine better integration of
pharmacists as members of the mental health care team in communities.
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Background
Pharmacists’ roles in the community pharmacy setting in
Canada and elsewhere in the world are expanding. Profes-
sional role revision in health care occurs in response to fac-
tors including, but not limited to, demands of the public
and changing expectations, challenges with accessibility, ad-
vances in technologies and treatments, shortages of health
care professionals, and increased health care costs [1]. In
mental illness and addictions care, many of these factors
co-occur alongside broader changes in the funding and de-
livery of health care such as shorter hospitalizations, fewer
inpatient beds, and increasing demands on physicians and
other primary care providers to care for people with serious
mental illnesses and addictions [2–5]. Ensuring that all dis-
ciplines are practicing to their full potential and scope in
mental illness and addictions care is one of many mecha-
nisms to facilitate overcoming these, and various other
challenges, such as enduring issues with timeliness, accessi-
bility, appropriateness of care, and continuity of care [5–7].
Pharmacists can impact various outcomes (e.g., improve
adherence rates, decrease prescribing of potentially in-
appropriate psychotropics) in mental illness and addictions
care [8, 9]. However, attempts to capitalize on the potential
benefits of pharmacists working within their full scope of
practice in mental illness and addictions care presents both
opportunities and challenges. A recent review [10] high-
lights opportunities for pharmacists in mental illness and
addictions care regarding the kinds of services they can
offer, how they offer them, and where they are delivered.
For example, pharmacists are increasingly participating in
multi-disciplinary teams, providing services outside of
community pharmacy contexts in what would be consid-
ered non-traditional settings for a pharmacist (e.g., patient
homes, primary care clinics), and engaging in activities be-
yond direct dispensing duties (e.g., depression screening)
[10, 11]. Challenges to enhancing pharmacists’ roles
include factors specific to the pharmacist, their practice en-
vironment, the patients, or other variables that may limit
pharmacists’ abilities in providing quality care in keeping
with standards of practice and the preferences of people
with lived experiences of mental illness and addictions.
Examples of these factors can include stigma, limitations
within the context of community pharmacy practice (e.g.,
staffing, unpredictable workflow, privacy issues, lack of
time), and issues with knowledge, skills, and competence
in medication management for mental illness and addic-
tions or other areas such as communication [12–18]. Lim-
ited or nonexistent remuneration for pharmacists’ services
has also been reported as an impediment to mental illness
and addiction service delivery in community pharmacies in
other areas of the world [18].
Inherent in the pharmacist’s role are medication
dispensing-related activities. Despite increasing preva-
lence of psychotropic prescriptions, medications with
the potential for misuse, and addiction pharmacotherapies
globally, and especially in Western cultures, research re-
garding the community pharmacists’ experiences in the
care of people with lived experience of mental illness and
addictions is limited. The majority of literature in mental
illness and addictions care has focused on the patients’ ex-
periences or outcomes (e.g., adherence, satisfaction) as a
result of pharmacists’ interventions [8–10, 13, 16, 19–34].
Studies of pharmacists in mental illness and addictions
care are primarily conducted using syntheses and survey
methods and have focused on: characterizing pharmacists’
roles; assessing pharmacists’ attitudes towards patients and
treatments; and obtaining perceptions around educational
needs [9, 10, 16, 35–44]. Surveys can contribute valuable
information and breadth regarding issues with pharmacy
service provision, but available qualitative studies [18, 45]
can allow for greater depth of understanding around the
pharmacists’ experiences and behaviours in the context of
their practice along with relevant challenges and opportun-
ities. This knowledge is extremely useful in designing inter-
ventions aimed to enhance pharmacy-based care of people
with lived experience of mental illness and addictions.
In our program of research, we have been working to
develop programs and interventions informed by an un-
derstanding of how and under what circumstances phar-
macists can effectively and efficiently engage in providing
services to people with lived experience of mental illness
and addictions in the context of the community pharmacy
setting. A critical component to intervention design and
development includes first understanding the behaviours
of pharmacists in the context of their practice and there-
fore, our work is underpinned by various behaviour
change theories and frameworks, including the Behaviour
Change Wheel (BCW) and the Theoretical Domains
Framework (TDF) [46–49]. This includes questioning who
needs to do what differently, when, where, and how, and
examining why the behaviours are enacted as they are in
context [47]. We also need to consider what likely needs
to change for the target or desired behaviours to occur
[47]. Use of these theories supports developing inter-
ventions and programs with targeted behaviour change
techniques that can overcome potential barriers to the
successful implementation for these programs [47].
Based on our knowledge of the existing literature exam-
ining pharmacists’ roles in mental illness and addictions
care, we determined that conducting a study using quali-
tative methods was appropriate to better inform the
design and development of interventions or programs
aimed at enhancing pharmacists’ roles in mental illness
and addictions care. Underpinning the conceptualization,
design, and analysis of the study with behaviour change
theory allows for a more systematic process for developing
our understanding of the behaviours in context and pro-
viding us with a better foundation in moving forward with
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future intervention design. We therefore conducted a
qualitative study to gain and extend knowledge and
understanding of the pharmacists’ experiences and behav-
iours in the practice context in providing services to
people with lived experience of mental illness and addic-
tions in the community pharmacy setting underpinned by
behaviour change theory [46, 47] and the TDF [48].
Methods
Design
We conducted a qualitative study using directed content
analysis [50, 51] guided by the TDF (see Table 1 for
domains), which can be used to understand behaviours of
health care professionals and implementation challenges
and opportunities for interventions in health care [48]. The
TDF was developed from 128 constructs from 33 psycho-
logical theories through an expert consensus process [52].
It was originally developed with 12 domains [52] and
further modified to include 14 domains and 84 component
constructs [48]. The philosophy behind the development
of the TDF was to make psychological theories relevant to
behaviour change and more accessible for disciplines, other
than psychology, who are involved in the design, develop-
ment, implementation, and evaluation of interventions in
health care [52]. The TDF has been used to understand
behaviours and implementation challenges in a variety of
settings and content areas in health care (e.g., transfusion
medicine, emergency care, hand hygiene, prescribing
errors) [53] and more recently, but to a limited extent, by
pharmacists [12, 54]. The TDF is a refined version of the
framework for understanding behaviour known as the
COM-B (capability, opportunity, motivation, and behav-
iour), which is at the centre of the Behaviour Change
Wheel [47]. Information gained from research using the
TDF can be used to help us understand behaviours and
challenges and opportunities in practice, and also inform
future intervention design by facilitating the use of the
BCW (Fig. 1) [47]. The TDF domains have been mapped
onto the COM-B (Table 1) [47, 48] at the centre of the
BCW. To illustrate, environmental context and resources
of the TDF are mapped to the physical opportunity in the
COM-B and therefore, interventions or behaviours that
are occurring because of specific issues within the envir-
onmental context reflect on limitations in the physical
opportunity to engage in the behaviours. For example, a
cardiovascular risk reduction program for people with
lived experience of mental illness is implemented in the
pharmacy but has little uptake by pharmacists because of
lack of time and difficulty experienced by pharmacists in
determining which patients would benefit most because of
inefficient workflow and the diversity of patients at the
pharmacy. Using the Behaviour Change Wheel, we can
then determine potential intervention functions and policy
categories that can be used in intervention designs to
overcome issues that have been identified towards the
desired behaviours [47]. Issues as described earlier within
the environmental context with lack of time and uncer-
tainty as to which patients would benefit are amenable to
restriction, environmental restructuring, and enablement
as intervention functions, based on the work of Michie
et al. [47]. Therefore, as in the example of the cardiovascu-
lar risk reduction program with little uptake, environmental
Table 1 Theoretical Domains Framework [48] coding frequency of pharmacists’ experiences in providing services to people with
lived experience of mental illness and addictions
Domain Corresponding part of COM-Ba system
from the Behaviour Change Wheel [47]
Coding frequency
Social/Professional Role and Identity Motivation (reflective) 130
Environmental context and resources Opportunity (physical) 67
Social influences Opportunity (social) 38
Beliefs about capabilities Motivation (reflective) 38
Skills Capability (physical) 28
Knowledge Capability (psychological) 26
Optimism Motivation (reflective) 21
Emotion Motivation (automatic) 17
Beliefs about consequences Motivation (reflective) 12
Reinforcement Motivation (automatic) 8
Goals Motivation (reflective) 6
Intentions Motivation (reflective) 2
Memory, attention, and decision processes Capability (psychological) 2
Behavioural regulation Capability (psychological) -
aCOM-B: C is capability, O is opportunity, M is motivation, and B is behaviour
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restructuring could include a computer report or on-
screen prompts to alert pharmacists to people at highest
risk for cardiovascular disease based on an algorithm with
imputed risk factors (e.g., age, medications that have the
potential for cardiometabolic side effects (e.g., some anti-
psychotics)). In this example, the pharmacists are taught to
use prompts/cues, which is considered one of numerous
potential behaviour change techniques [47, 55, 56].
Our work in this study is situated in the early stages of
intervention design, in which we attempt to understand
the pharmacists’ experiences and behaviours in context
with the use of the TDF, which, as previously stated, is a
refined version of the framework for understanding behav-
iour (i.e., the COM-B) in the Behaviour Change Wheel.
Study participants
We used convenience sampling and recruited pharmacists
using multiple mechanisms including advertisements
through professional association newsletters, the Internet
(e.g., classified advertisement sites such as Kijiji), and
word-of-mouth. Pharmacists were eligible to participate if
they were licensed to practice and had experience in
providing pharmacy-based services, which included dis-
pensation of psychotropics, at a minimum, to people with
lived experience of mental illness and addictions. Partici-
pants were paid a one-time honorarium for participation.
Data collection and analysis
A semi-structured interview guide (Additional file 1) was
drafted by two research team members (ALM, DMG)
after reviewing the literature and based on tacit knowledge
of mental health care and community pharmacy practice.
The draft was sent to other team members (RMM, SPK)
for review and feedback. Based on feedback, the guide was
refined and revised and subsequently pilot-tested with
four senior pharmacy students, a medical student with a
Masters degree and research background in mental illness
and addictions care, and two community pharmacists. All
were given background information regarding the purpose
and objectives of the project. Questions were examined
for understandability, relevance, clarity, and fitness for
purpose. Comments and feedback were collected and revi-
sions to the guide were made prior to finalization.
Recruitment occurred during June and July of 2012.
Pharmacists were offered the option of interviews or focus
groups for pragmatic reasons given our knowledge of the
challenges with scheduling and staffing in pharmacies. We
recognized that focus groups and interviews would give
different kinds of information. For the purpose of our study
and intended use of the findings for future intervention
design, the integration of data would give complementary
views of the phenomenon as well as the potential for
greater depth and breadth [57]. All encounters with partici-
pants were digitally audio-recorded and subsequently
transcribed. Transcriptions were read twice along with the
audio for cleaning and anonymizing of personal informa-
tion of pharmacists and patients. All data were collected
during June through August of 2012. We aimed to recruit
at least ten pharmacists to achieve saturation with TDF
coding given the scope of our study and our intention to
use information from the TDF coding and themes in pro-
gram and intervention development [58, 59].
A directed content analysis approach was used with
the TDF and its constructs serving as the coding scheme
for the codebook. We adhered to the definitions of the
14 domains, and 84 constructs within these, as described
by Cane et al. [48], and these served as our coding defi-
nitions. Four members of the team (ALM, HP, SH,
Fig. 1 The Behaviour Change Wheel [47]. From Michie et al. [47], BioMed Central, Implementation Science
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DMG) coded the transcripts using directed content ana-
lysis. Prior to coding each transcript, we familiarized
ourselves with the data through reading the transcripts
several times to develop “a sense of the whole beyond
the immediate initial impression” (p.143) [60]. We then
read and coded one transcript initially and then met to
discuss coding. We reviewed the TDF domains and
provided exemplars from our coding to ensure we had
clarity regarding meaning. We proceeded to code the
remaining transcripts and met following the completion
of each to discuss coding and main themes surrounding
the TDF coding. Intercoder reliability based on percent-
age agreement was between 80 and 90 % for codes.
Two team members (ALM, DMG) were responsible for
theme development. We followed modified procedures
outlined for thematic analysis [61, 62]. The analysis stages,
which co-occurred with our directed content analysis,
included [61, 62]: familiarizing ourselves with the data;
deductively coding and “flagging” meaningful data ele-
ments with each transcript analysis [60]; and searching for
themes, reviewing themes, defining and naming themes
through bringing coded data together and “interrogating”
[60] relationships among TDF codes and themes. Theme
development occurred independently at first and subse-
quently over the course of six, 1 to 2-hour meetings,
themes were refined, debated, and finalized. All members
of the team reviewed and critiqued the findings. Data were
managed with QSR NVivo 10 [63].
Ethics
Ethics approval was received from Capital District Health
Authority Research Ethics Board (CDHA-RS/2013-042),
which has reciprocal ethics in place with Dalhousie
University Research Ethics.
Results
We conducted one focus group (66 min) with four partici-
pants and two interviews (44 and 54 min) with practicing
pharmacists (n = 2 males, n = 4 females;164 min of total
data). Three staff pharmacists, one owner, and two man-
agers participated, and all were from different pharmacies.
Participants characterized their practice as urban (n = 4),
suburban (n = 1), and rural (n = 1) based on general popu-
lation estimates. The mean participant age was 35 years
(range 29 to 43). The average hours worked per week was
41 (range 35 to 50) and years in practice ranged from 6 to
17 (mean 9.2). Monthly psychotropic prescription propor-
tion estimates ranged from 30 to 80 %. Five pharmacists
reported regularly dispensing methadone maintenance
therapy. Four additional pharmacists were interested in
participating initially but did not; one could not be
reached to determine the reason for absence and three
canceled just prior to the session due to conflicts.
Theoretical domains framework
The most commonly occurring codes from the TDF
were social/professional role and identity and environ-
mental context and resources (Table 1).
Themes
We identified five key themes from pharmacists’ experi-
ences of caring for people with lived experience of mental
illness and addictions including: 1) competing interests, de-
mands, and time; 2) relationships, rapport, and trust; 3)
stigma; 4) collaboration and triage; and 5) role expectations
and clarity. Although individual themes are separate and
important in their own right, there are linkages among
themes in the experiences of pharmacists. For example,
evidence supporting competing interests, demands and
time and stigma were also linked with impacting the
abilities of the pharmacists and patients in forming rela-
tionships, establishing rapport, and trust.
1. Competing interests, demands, and time
Pharmacists in the community pharmacy setting
were challenged to balance competing interests and
demands on their time and many of these centred
around business practices. Most of the supporting
information from this theme came from codes
within environmental context and resources, social
professional role and identity, and to a lesser extent
social norms. All pharmacists mentioned not having
enough “time” for patients, which they
acknowledged was necessary for caring for all
patients but especially for those with lived
experience of mental illness and addictions. The lack
of time was a representation of many underlying
issues such as a lack of resources with staffing, an
inability to predict or control workflow, and
inefficiencies in the workflow process. Issues with
human resources and managing workflow directly
affected their abilities to provide care and attention
for those with mental illness and addictions.
Regardless of the pharmacist’s role within the
pharmacy (i.e., owner, manager, staff pharmacist),
they were keenly aware of how competing interests
and demands for their time and attention impacted
their care of patients vis-à-vis the business aspects of
pharmacy practice.
Pharmacists discussed ideas, including different
compensation models, to improve issues, albeit with
skepticism and recognition of various tensions:
“FGR1 (Focus Group Respondent 1): … it’s a weird
profession we’re in. We’re in a health profession as
well as retail. And so it’s hard to reconcile those two.
… Yes, I think if you would have more compensation
for the time. But I don’t really see how that would
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work very effectively the way that things are run now.
FGR2: If you did have, though, fee-for-service, you
could schedule in appointments for people. You know,
so that you could have an extra pharmacist there in
the morning. The pharmacist, because they’re getting
paid extra, could go off [to be with the patient], take
extra time. If people would be willing like to make an
appointment to come in to talk about their medica-
tion. And I think people probably would, especially
the people that come to the pharmacy all the time.
FGR3: If they weren’t paying for it. FGR4: Oh, yes,
they’re not paying for it, no. But if drug plans and so-
cial services and stuff recognized and paid for it.
FGR3: I just don’t see them ever paying for it because
that’s pretty much part of our job, is to like go
through the medication. I don’t think they’re going to
pay extra for spending that extra little time.”
One pharmacist, who changed jobs to move into an
ownership role, described her previous experience as
a staff pharmacist with little control and power in
managing competing demands. She was asked to use
an abbreviated counselling approach (i.e., “Reader’s
Digest” version) to provide more time for revenue
generating activities such as filling prescriptions:
“Interview Respondent (IR) 5: I wanted to be a
pharmacy owner, just not to be told how I’m going to
spend my time or how I’m going practice pharmacy.
I’ll do it the way I want to do it. … when I worked in
[town] … I was criticized for spending too much time
with customers. And if I heard one more time about
how I had to deliver the Reader’s Digest version. … I
hated that. I would spend enough time. And sometimes
people needed more time than others.”
These abbreviated styles for patient counseling and
education were reflected in the use of pharmacists’
language with “spew”, “spiel”, “bare bones”, “cut if
off”, etc.:
“FGR3: … you can get all your main points out [during
counselling]. You take time to do that. You just don’t
have time to sit there and chat with them and give …
the rapport … encouragement and whatnot that they
might need. … FGR2: Yes, it’s the bare minimum. …
what the medication is for, the directions, side effects …
And just really bare bones and if they have any
questions. Then you’ve got someone else waiting for
you. … you kind of have to spew out what you need to
say. FGR3: … if it’s not busy, you can be like, “So how
are you feeling?” … But most of the cases, it’s busy. …
you just have to cut it [the discussion] off. FGR4: … It’s
definitely dependent on how busy it is. … if you have
three or four people at the counter, it’s hard to manage
it. FGR3: And when I think back a couple of years ago
when we did have [pharmacist] overlap … I would be
more apt to do like follow-up calls, callbacks to see how
they were making out. And now that just pretty much
doesn’t exist. Which is unfortunate.”
2. Relationships, rapport, and trust
All pharmacists acknowledged the importance of
building relationships with people with lived
experience of mental illness and addictions and
consistently used words like “rapport” and “trust”.
This was seen as essential in the pharmacist-patient
relationship for accepting advice and getting “buy-in”:
“FGR2: … if you can build up the rapport with the
individual, and you get buy-in … then what you say
has more weight with them. So maybe when you do
talk to them about things, that, you know, you’ve built
up this trust and then they kind of go with that more
if you have the time to build up that relationship. But
if you don’t have that then, you know, you’re just an-
other face in a white coat.”
This was echoed by another pharmacist discussing
issues around addictions to medications including
items available for purchase without a prescription
(e.g., acetaminophen with codeine or Tylenol® No. 1)
and building confidence in getting “buy-in” before
refusing sales of these items:
“IR5: I have one person that has alcoholism and I’d see
her buying a fair amount of Tylenol 1 s. … I transferred
some prescriptions for her … lithium and … I think I
made some Antabuse® for her. And then of course that
opened up the discussion … we talked a little bit about
the Tylenol® with codeine use, and [I] asked her how she
was using it. … that kind of prompted the discussion
that … I certainly can’t keep her from buying it because
she can go elsewhere, but was she okay with me not
selling it to her anymore, because I didn’t feel
comfortable selling it to her. I wasn’t helping her. And
she really appreciated that. … But just trying to talk
openly about it. … I don’t like the idea of just denying a
sale just based on a suspicion if I haven’t got their buy-
in. … if I haven’t discussed with them about … why I
can’t sell it to them … I’m not doing them any favours
by selling it to them. I’ve seen other alcohol addictions
as well and usually people are pretty open about talking
about that stuff with me. … I guess I’m more confident
doing that [discussing acetaminophen and codeine use]
because I had an incident when I worked in another
town, and I had a young man come to me … he used to
buy a lot of Tylenol® with codeine so we had the
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conversation about … what he was using it for. And it
was chronic back pain. … I saw enough of him to know
that he was using it pretty regularly. But then after
maybe a year or 2 years, he came to me after being in
rehab and telling me that he had a problem. He was ask-
ing me not to sell it to him anymore. … So that helped
me to be more open in terms of asking people … I’m
not always feeling like I’m intruding. I feel my intention
is to help them, and it will come across that way.”
The pharmacists recognized the importance of
privacy and confidentiality in rapport and
relationships and this was also tied in with stigma:
“IR6: … people don’t want to stand in the middle of
the aisle and talk [about] how their antipsychotic is
working. But they wouldn’t mind saying, you know,
how is your pain medication for your back that you
threw out last week? So it’s a different kind of a
sensitivity. … I tend to take those people, like I
mentioned, over off to the side somewhere or to our
private counseling area, and just have a chat with
them. … They require a little bit more privacy for a
conversation before they’re willing to open up.”
The lack of privacy in the pharmacy environment
significantly impaired some pharmacists’ abilities in
their relationships with patients:
“FGR2: It’s extremely difficult. … I was counseling a
patient today on … a new antidepressant and a new
antipsychotic. And I don’t even have like the barriers
[privacy partitions]. … Meanwhile, there’s like three
patients at the counter. … I have a sign posted – “Please
respect patient’s privacy and stand back”. But nobody
respects it … it makes the patient probably not as apt to
either listen or want to hear.”
Descriptions of relationships with people identified
as having addictions were different than those
without addictions. They were discussed in a
manner best described as strained and tentative and
pejorative terms were used more often. Stigma was
also linked within these excerpts but the
predominant theme was relationship, rapport, and
trust. At times, there was mistrust discussed by
pharmacists about their patients and their
perceptions that patients were not trusting of the
pharmacist. There was also a lack of clarity around
whether patients actually had an addiction such as
in many examples provided of patients misusing
prescription medicines. One pharmacist in the focus
group discussed “awkwardness” in the relationship
with those experiencing addictions:
“FGR3: … but when I first mentioned about the
awkwardness, you don’t get that with many patients
except for the addicts, and sometimes the mental
health patients who are abusing their drugs and not
using them properly. I don’t know if you’d classify
them as addicts but if they’re using benzos or
something like that for their anxiety then, you
know, they might be using them more than
appropriate. So you’d get that kind of awkward
interaction that you wouldn’t get with people on a
heart medication.”
3. Stigma
Stigma and its impact on patient care and relationships
was concerning to pharmacists. Pharmacists also spoke
of their own views that may have been influenced by a
stigmatizing culture and how this evolved through
their education and training to becoming a practitioner
and working with patients:
“IR6: … you hear the word antipsychotic or you hear
the word bipolar disorder and it kind of makes you
envision the kind of person who’s going to require
these medications. But they are, you know, for the
most part, very “normal” individuals … when I did
graduate, it was kind of taking the blinders off of what
does mental illness actually look like and what does it
not necessarily look like.”
One pharmacist in the focus group assumed the
patient’s perspective to consider what they would do
in relationships with health care professionals based
on a culture of stigma and if the public perceived a
limited role for the pharmacist:
“FGR2: … if I had like a mental health issue, I
wouldn’t just open up to everybody about it because
there’s a stigma about people with mental health
issues. … “there’s something wrong with them…” or
whatever the stigma is. So if I then don’t see my
pharmacist as a health professional, if I see them as a
pill counter, then I’m not going to open up to them.
… when I go to a doctor’s office, my doctor is my
health professional and that’s who I’m talking about
my issues with. If I’m just picking up my pills then
I’m not going to get into what I’m all about.”
The issues of stigma were also discussed in terms of
other supports for the patients including community
and family. Participants practicing in “small”
communities discussed having more challenges with
stigma. The impact of stigma on patients in their
homes was discussed and one pharmacist described
their approach and solutions to mitigate this stigma,
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such as discussing information with family members
to educate and inform them.
“IR5: If they’re comfortable with their family being
there then we try to have the discussion with
everybody. Because again, there’s always the stigma.
You know, you can talk with the patient all you want
and give them a good understanding but if they have to
go home to an environment where somebody might be
saying, “… you’re crazy, you’re out of your mind, you
don’t need those [medications],” or whatever.”
Some of the language used by pharmacists during
the focus group demonstrated that they relied on
externalizing features and the kinds of medications
people used to characterize patients who may
require certain services for mental health and
addictions problems:
“FGR4: … it’s based on prescriptions that come in. …
their appearance sometimes. For people dependent on
opioids, their appearance is a little different from the
regular clientele. They could have scabs or skinnier …
not as well kept kind of thing. … FGR1: Yes, their
mannerisms too.”
4. Collaboration and triage:
Pharmacists discussed collaborating with several
health care professionals such as physicians and
social workers. Other individuals and representatives
of community groups including police were also
discussed. The nature of collaboration was often
presented in the context of needs of the moment or
in a reactive fashion. Successful collaborations were
often the result of serendipity. The desire to have
resources and knowledge of appropriate mechanisms
for triage and community resources was evident.
“FGR4: … things like refills, liaising with the doctor
about medication issues. Then sometimes it’s just
plugging them into other resources that are out there
available. … if they’re [patients] coming in saying, “Well,
I need to get this,” then you can refer them to the social
worker or there’s the [organization], the [community
group]. … A lot of times I find they run into issues with
the [prescription] co-pays with social services. So there’s
a lot of back and forth with the social workers …”
One pharmacist described a serendipitous,
snowballing approach to successful collaborations
and triaging patients based on needs:
“IR5: … I know I had a young girl who … could benefit
from a psychologist. So I called and just tried to make
some contacts for her … to get her in to have services.
… through people that I met … people in mental health
and psychologists, and then just going from there and
making the phone calls. … [I] make the phone call and
then have them steer me in the right direction. … I’ve
always had good luck … that they know how to point
me in the right direction. … I think I was very fortunate
to have met the kinds of people that I did in my
profession. … initially starting off years and years ago,
that mental health nurse and then the psychologists [I
met] along the way. … if we’re talking about building
teams … it would be great to have these [education]
programs with other individuals. … nursing and
psychologists and with doctors, everybody in the same
room. … And mainly teaching us where to access help.
… like who to call.”
Because of pharmacists’ roles in dispensation of
opioids and many other medications with the
potential for misuse due to physical or psychological
dependence, the pharmacists described collaboration
with police but for some, this relationship was tense:
“FGR3: I had a police officer, he had to get a search
warrant because he had suspicions of one of our
patients selling his [opioid]. But he was pretty harsh
on me. He kept asking me and asking me. And I was
like … “… no, you really need to go get your search
warrant because I’m not answering any more
questions.” … they can be a little bit tough if they
suspect something of your patient. So that wasn’t a
very positive experience with the police officer.”
5. Role expectations and clarity:
Pharmacists discussed participating in many
activities that are in their current scope of practice
but with some grey areas and blurred lines as to the
boundaries of pharmaceutical care and support
extending outside of these bounds. Lack of clarity in
role and boundaries was a phenomenon that created
tension among some pharmacists. These situations
were exemplified through stories of pharmacists being
a listener for patients, either over the phone or in
person, with and without direct relevance to
medication-related duties. This was aptly demonstrated
by a pharmacist’s interaction with a grieving patient:
“IR5: … she had a lot that she wanted to talk through.
And I was criticized [by other pharmacists] because
I’m not a counsellor, I don’t have to have those kind
of conversations with her, I should have broken it off
a lot sooner. But if she wants to talk about her
[relative], I’m going to let her talk about her [relative].
And my intention was never to be a counsellor for her.
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My intention was just to be a listener for her. … I was
talking with her about her antidepressant but what she
wanted to do was to talk about her [relative], I’d let her
talk about her [relative]. Not for that long a period of
time, and I wouldn’t be offering advice. …”
In addiction-related care, pharmacists in the focus
group discussed situations at length, in which they
were an intermediary between patients and doctors
related to the dispensation of controlled drugs and
substances. They did not feel consistently supported
in their role by other health care professionals or
their patients as demonstrated in many examples.
They also discussed at length the tools and tech-
niques they used when “saying no” to patients seek-
ing their prescription medication refills prior to their
due date. This commonly included citing regulatory
standards, reimbursement issues, or physician unavail-
ability as reasons to postpone access to a controlled
prescription medication. They also acknowledged vari-
ability in how pharmacists handled these situations
with some pharmacists taking a more flexible approach
and allowing early prescription refills. Communication
issues with physicians were also noted in describing
situations in which the physician was aware and had
permitted more medication use than what was origin-
ally intended with the prescription but the pharmacist
was not made aware.
“FGR2: … she [patient] was like 14 days early on a 90-
day supply [of clonazepam]. And she had put it on our
computer-automated system. … the computer-
automated system doesn’t know whether it’s a benzo or
a narcotic. And she said, “Well, it told me it would be
ready today.” And I was like, “Well, unfortunately… It is
14 days early.” … “The best I can do is call your doctor
on Monday because this is a controlled drug so I can’t
dispense it early.” … I did explain everything but she
took off and she was really mad. … But that’s … a typ-
ical situation. Some people will handle it better than
others. And perhaps having another pharmacist that
may have dispensed it 14 days early that I work with
might have created a bit of anger towards me. … It
ruins your day because you don’t want anyone walking
away from you like huffing and puffing and being angry.
… FGR3: … It makes you a bit nervous because what if
you then go and call the doctor and they’re like, “Oh,
give it to them. That’s fine if they’re using a little bit
extra.” Then it really makes you look like the bad per-
son. FGR4: I disagree because I think that we’re still
doing our job. … FGR2: But if they’ve been so mad at
you and maybe they’re telling you … the doctor said
they could take it more often sometimes, but you can’t
take their word. And then the doctor does say, “Oh,
yeah, I told her she could take it more often some-
times.” Then you’re just this person who’s made like a
bad moment for everyone. FGR1: … I guess I’d be hid-
ing behind the rules and regulations and say, “You
know, I’d like to do it but I’ve got to do it this way or I’d
lose my license.” FGR3: … This is my license on the
line. FGR1: And they’d [patients] tend to get that.
FGR2: Sometimes drug plans will save me too because
drug plans won’t pay for stuff early. And the patient
won’t be willing to pay for it. So that’s an extra …
FGR1: … safeguard, yes.”
The pharmacists further addressed the physicians’
roles in the pharmacist-physician and patient-
physician relationship in various situations such as
when patients were requesting medications early:
“FGR3: Hopefully to support us. But they’re not all
like that. Some of them just give in to the patients
time and time again. FGR4: Even like the addiction
specialists … I’m often on the phone with them and
they’re … it must be a really tough thing to be a
physician as well because maybe a patient that has,
you know, an addiction to a narcotic says, “Well, if I
don’t get my narcotics, I’m going to go off and do
this.”… I guess to give in is the lesser of two evils. …
often doctors are too easy to give in to patients that
are chronically abusing and chronically getting their
medications filled early with a different excuse each
time. Or they spilled their methadone … I think the
physicians are giving in too easy. Which sort of takes
away from our role as well because we’re trying to
control them. We’re trying to get them off this
medication. FGR3: Yes. When you have those types of
doctors, sometimes you don’t go that route because
you know the doctor is going to say, “whatever”. So
with those types, you kind of put notes in their file –
“Don’t give early”… FGR2: But the patient will contact
the doctor anyway.”
Pharmacists then attempted to name this part of
their role:
“FGR4: Ethics. FGR1: Gatekeeping. [laughs] FGR2:
Medication police, or trying to be. FGR3: Protecting
patients. I mean I’ve had some patients come back
when they’ve got maybe a little bit better and thank me
for being on top of not giving them stuff, and that kind
of thing. I mean it doesn’t cure them and they usually
fall back into it but some patients are appreciative. So I
guess you’re just trying to help them and protect them.”
Pharmacists were often passive in their role, as if
their role was peripheral to caring for people with
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lived experience of mental illness and addictions.
Many of these quotes were grouped under social/
professional role and identity and also social
influences. This was most obviously demonstrated
when pharmacists discussed patients’ diagnoses.
Pharmacists were relying on medications and
combinations of medications to determine, or as one
pharmacist said, “guesstimate”, what diagnoses
patients had versus inquiring directly about the
indication:
“FGR4: … Nobody has ever said to me I have
depression or I have schizophrenia. I’ve never heard
anybody say that to me. FGR3: You can ask them a
couple of questions about what symptoms they’re
experiencing or what the doctor has told them, and
sometimes that will reveal a little bit of information.
But for the most part, I feel like they just keep quiet
and they want to listen and get out of there. Then they
might call later with questions. It depends on the
person. If they’re dropping off an antipsychotic
[prescription], I don’t think that most of them are
asking a thousand questions and willing to give a lot of
information. FGR2: You just kind of guesstimate based
on the therapy. … if they’re just getting maybe one
antidepressant, that they maybe have minor depression
or maybe anxiety … If they’re big into antipsychotics …
then you would guesstimate that they have something
more severe, more troubling. But you don’t very often
get their actual diagnosis, I suppose.”
Discussion
Our study is one of a few qualitative explorations of phar-
macists’ experiences in mental illness and addictions care
[12, 17, 18, 23, 45] and adds further understanding to the
pharmacists’ experiences and behaviours in the context of
practice. The findings point to significant challenges in
practice. It is also uniquely underpinned by behaviour
change theory and the application of the TDF as an
analytic framework, which proved useful and effective for
coding and theme development for the pharmacists’
experiences with people with mental illness and addic-
tions. These findings can inform the choice of various
intervention functions and policy categories used in the
design and development of interventions for community
pharmacists in mental illness and addictions care. Based
on our work, consideration of several TDF domains in
new program/intervention design and development, espe-
cially social/professional role and identity, environmental
context and resources, beliefs in capabilities, and social
influences, is required to support community pharmacy-
based care of people with lived experience of mental illness
and addictions.
Environmental context and resource issues were particu-
larly influential in directing pharmacists in the care of their
patients in our findings. This was especially evident in the
theme competing interests, demands, and time. Issues with
time, manifesting from workflow inefficiencies and inad-
equate staffing, and lack of privacy limited pharmacists’
ability to care for people with lived experience of mental
illness and addictions beyond basic medication-related ser-
vices. This finding is similar to what pharmacy students
observed of their work environments with “business ten-
sion” directing many actions of pharmacist supervisors and
preceptors [12]. Although several of the pharmacists in our
study did not perceive providing any additional services
other than medication counseling, compliance packaging,
and opioid substitution treatment services, they did in fact
provide examples of other valuable actions for patients in-
cluding health care system navigation, triage support, and
referrals to community groups and health care profes-
sionals. Many of the services were offered through both
face-to-face and telephone interactions and outside the
context of a medication-related issue. Although various
methods have been used to quantify pharmacists’ activities
[64] and how pharmacists perceive their workloads, [65,
66] we are not aware of any research that examines the
non-medication related interventions by pharmacists such
as health system navigation and making referrals for men-
tal illness and addictions care. It would be valuable to
examine these encounters between patients and pharma-
cists to determine the range and extent of activities that
pharmacists are doing in non-medication consultations
and what impact these activities have on patient outcomes,
the pharmacy practice environment, including impacts on
quality and safety, and the broader mental health system.
Issues related to pharmacists’ roles and identity were
prevalent in our study and this was especially evident in
discussions of people with addictions and within the
theme of collaboration and triage. The nature of the rela-
tionships among participant pharmacists, prescribers, and
patients was not entirely supportive or positive as pharma-
cists acted as the intermediary between patients and doc-
tors, or as they labeled it, “medication police” and
“gatekeeper”. The participants expressed the desire for
better relationships and the need for more collaboration,
communication, and consistency with other health care
professionals and patients. Communication challenges be-
tween physicians and pharmacists have been found to be
prevalent in the care of people with lived experience of ad-
dictions [41, 67]. Participants described various examples
of communication issues and other complex problems
with people with lived experience of addictions to over the
counter products (e.g., acetaminophen with codeine),
alcohol, benzodiazepines, and opioids. The participant
pharmacists had differing perspectives on their role, but
it was primarily limited to technical and legal aspects of
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dispensation. Similar to a survey of pharmacists in Indiana,
US [38], the care provided by pharmacists for people with
addictions was time intensive. Our findings provide add-
itional insights into the extent and range of issues includ-
ing the layered complexity in negotiating with patients and
physicians and especially in time intensive activities around
issues with medication supply (e.g., early medication refills
with benzodiazepines and opioids, spilled doses of metha-
done). Similar issues have been reported by a sample of
pharmacists providing opioid substitution treatment in
Australia in which argumentative behaviours regarding
supply such as takeaway doses, which are important for
convenience and maintaining normality for many patients
[68], were one of the more common problematic aspects
in care [42].
Social influences in the context of the pharmacy envir-
onment are also important to note and especially when
considering attitudes and behaviours of all pharmacy staff
with respect to stigma. Group norms and conformity,
including use of pejorative terminology, could contribute
to the continued stigmatization of vulnerable groups of
people. Although there has been progress made in lessen-
ing stigma in many areas of health care, there are still ex-
amples from the pharmacy context, which negatively
impact the care of patients [33, 35, 45, 69–80].
The beliefs about capabilities domain, inclusive of con-
structs such as self-efficacy and professional confidence,
was also prominently coded and within the themes around
role expectations and clarity and relationships, rapport,
and trust. Looking to future intervention development,
capitalizing on aspects of intervention design that work to
enhance reflective motivation hold promise for encour-
aging desired behaviours. For example, recent work using
interactive educational workshops improved pharmacists’
self-efficacy for documentation of care, which will inher-
ently be required for improved community pharmacy-
based mental illness and addictions care [81]. Other re-
search has also demonstrated that adopters of innovations
in pharmacy service delivery are more likely to be those
with higher perceived self-efficacy [82].
Participant pharmacists also discussed wanting more
interdisciplinary education and training on the services
available for patients, how to help patients access these
services, and general therapeutic-based information on
addictions and mental illnesses. This is an important area
to further explore given pharmacists receive little formal
training in addictions and that more than half of pharma-
cists may never refer patients to drug treatment programs
[36] despite the fact that most pharmacists perceive pre-
scription drug abuse, including opioids intended for pain,
to be a problem in their practice setting [43]. Inadequacies
in pharmacists’ competencies, attitudes, and behaviours
have been cited as barriers to optimal care for people with
lived experience of addictions [38, 45] and these domains
may be improved by education and training. For example,
additional education and training increased the likelihood
that pharmacists provided patients with information on
addiction treatments and care [44]. Based on our findings
and the scope of the issues, there appears to be significant
opportunity to improve addictions care by pharmacists in
community pharmacy settings, but improving knowledge,
attitudes, and behaviours through education and training
is only a component of this complex area. Substantial im-
provements will be required in structures and processes in
the community pharmacy setting and the broader health
system, including those related to communication, collab-
oration, and following best-evidence based care in addic-
tion practice among health care professionals, in order to
better support community pharmacists in their role.
Finally, the care of patients by our pharmacists appeared
to be restricted through passive and peripheral involve-
ment with aspects of care, including having limited to no
knowledge of the patients’ diagnoses. Current practice
standards recommend that pharmacists keep information
regarding medical conditions in patient profiles to ensure
appropriateness of therapy and facilitate recommenda-
tions. Pharmacists use information on diagnoses not only
to assess appropriateness but also to tailor education and
advice about the use of medications and expectations
around benefits and adverse effects that are often linked
with diagnoses. Implementation of electronic health re-
cords that are used health system-wide may facilitate the
pharmacists’ access to information such as diagnoses, up-
to-date dispensing records, and laboratory values, but the
utility of these records may be variable and dependent on
a number of factors (e.g., privacy and confidentiality, ac-
curacy of the information, pharmacist role, the practice
environment, collaboration with other health care profes-
sionals) [83, 84]. More work is needed regarding better in-
tegration of community pharmacists from the periphery
into mental health care delivery in community settings.
Limitations
Given the nature of this research, there may be more than
one interpretation of the data, including different ap-
proaches to coding and thematic development. Members
of our team include pharmacists with views shaped by
disciplinary socialization and intimate knowledge of the
milieu of practice. We attempted to foster reflexivity by
having multiple team members, including those with
different backgrounds, and by writing our thoughts via
journaling throughout the study with particular attention
to our biases.
Using a directed content analysis approach with the
TDF, as in this study, forces the categorization of some
attributes and constructs that are closely related and ne-
cessary for pharmacists’ interactions with patients, into
Murphy et al. Substance Abuse Treatment, Prevention, and Policy  (2016) 11:6 Page 11 of 14
different domains. For example, behaviours related to
knowledge and skills are categorized separately but when
combined, as would be the case in training programs to
improve pharmacists’ capabilities in mental illness and
addictions care, they were coded 54 times. The separ-
ation of these may result in different behaviour change
techniques, intervention functions, and policy categories
used within intervention designs. Although both know-
ledge and skills fall within capability when mapped to
the COM-B, physical capability is mapped only to skills.
There is the possibility that skills may therefore not be
addressed adequately in a new intervention that primar-
ily uses education, as this intervention function is linked
to improving knowledge (psychological capability).
The number of participants was small although we ob-
tained rich data, saturated our TDF coding, and determined
that more data would not necessarily provide helpful infor-
mation for our goal of future intervention development.
However, we may have erroneously concluded that we
reached saturation. We recognize the concept of saturation
is debated and can be “highly problematic” [60], depending
on the research question, and we cannot presume that we
have all necessary data to understand a clinical
phenomenon in its entirety. In our assessing the reliability
of our coding we also used percentage agreement, which
does not account for random agreement among coders.
Using a technique such as maximum variation sam-
pling may have given us more diverse participant repre-
sentation. We also included data from both focus group
and interviews in our analysis, which may produce dif-
ferent information such that interviews can often give
depth on a topic and focus groups may provide breadth
and are also inherently subject to “group think”. Given
the small number of participants, anonymizing phar-
macy names and type (i.e., franchise, independent, etc.)
to protect confidentiality was necessary and therefore we
did not comment on how the pharmacy type may have
influenced behaviours, which has previously been shown
to impact pharmacists’ practices [85].
Conclusions
Five main themes characterize the pharmacists’ experi-
ences of caring for people with lived experience of mental
illness and addictions including: competing interests,
demands, and time; relationships, rapport, and trust;
stigma; collaboration and triage; and role expectations and
clarity. Pharmacists are not practicing to their full scope
of practice in mental health and addictions care for several
reasons including limitations within the context of the
work environment and lack of structures and processes in
place to be fully engaged as health care professionals.
More research and policy work are needed to examine
better integration of pharmacists as members of the men-
tal health care team in communities.
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